Ceryvyn Therapeutics Limited CYVNY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 216.10M | 203.43M | 191.03M | 13.95M | -164.62M |
| Total Depreciation and Amortization | -- | 44.80K | 88.70K | 88.70K | 88.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -221.99M | -245.39M | -268.30M | -124.45M | 19.86M |
| Change in Net Operating Assets | -2.42M | -8.01M | -13.49M | -13.49M | -13.49M |
| Cash from Operations | -8.31M | -49.92M | -90.68M | -123.90M | -158.16M |
| Capital Expenditure | -- | 0.00 | 0.00 | -6.50K | -13.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 0.00 | 0.00 | -6.50K | -13.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -30.89M | -30.91M | -30.94M | -15.54M | -140.00K |
| Issuance of Common Stock | -- | -- | -- | 25.84M | 51.69M |
| Repurchase of Common Stock | -- | -5.10M | -10.20M | -10.20M | -10.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -20.24M | -23.52M | -26.74M | 208.60K | 27.60M |
| Foreign Exchange rate Adjustments | -379.30K | 1.22M | 2.78M | 7.27M | 11.88M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.93M | -72.23M | -114.63M | -116.43M | -118.70M |